Purchase Of Shares In Amylyx Pharmaceuticals Inc. (AMLX) By VIKING GLOBAL INVESTORS LP


At the last check on Friday, Amylyx Pharmaceuticals Inc.’s (NASDAQ:AMLX) stock was up $1.05, moving up 2.80 percent to $38.60. The average number of shares traded per day over the past five days has been 584,877 shares. 5 times new highs have been achieved over the past 5 days, with a $3.71 gain in that time frame. In the last twenty days, the average volume was 729,299, while in the previous 50 days, it was 1,231,226.

Since last month, AMLX stock rose 0.40%. Shares of the company fell to $32.69 on 11/07/22, the lowest level in the past month. Since the beginning of this year, AMLX’s stock price has risen by 107.80%. However, the stock has declined by -0.43% since its 52-week high.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


AMLX stock investors should be aware that Amylyx Pharmaceuticals Inc. (AMLX) stock had its last reported insider trading activity 77 days ago on Sep 09. VIKING GLOBAL INVESTORS LP, the 10% Owner of the company, disposed of 700,000 shares for $30.23 on Sep 09. It resulted in a $21,159,753 divestment by the insider. VIKING GLOBAL INVESTORS LP sold 700,000 shares at an average price of $29.37 on Sep 08. The insider now owns 2,075,470 shares following the transaction. On Jul 06, 10% Owner ALS Invest 1 B.V. sold 60,609 shares at $20.70 apiece. The transaction was valued at $1,254,642.

Financial Health

In the three months ended June 29, Amylyx Pharmaceuticals Inc.’s quick ratio stood at 5.30, while its current ratio was 5.30, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 50.10% percent. Based on annual data, AMLX earned $82.97 million in gross profit and brought in $0.28 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 54.70%. Return on equity (ROE) for the past 12 months was -172.50%.

AMLX’s revenue rose 100.0% during the quarter, while net income inched up to $0.35 million. While analysts expected Amylyx Pharmaceuticals Inc. to report -$0.87 quarterly earnings, the actual figure was -$0.93 per share, beating the consensus estimate by -6.90%. During the quarter, the company generated -$54.6 million in EBITDA. The liabilities of Amylyx Pharmaceuticals Inc. were 37.41 million at the end of its most recent quarter ended June 29, and its total debt was $7.07 million. The value of shareholders’ equity is $66.26 million.

Technical Picture

This quick technical analysis looks at Amylyx Pharmaceuticals Inc.’s (AMLX) price momentum. With a historical volatility rate of 35.00%, the RSI 9-day stood at 70.60% on 23 November.

With respect to its five-day moving average, the current Amylyx Pharmaceuticals Inc. price is up by +10.69% percent or $3.71. At present, AMLX shares trade +6.75% above its 20-day simple moving average and +86.55% percent above its 100-day simple moving average. However, the stock is currently trading approximately +24.47% above its SMA50 and +95.87% above its SMA200.

Stochastic coefficient K was 91.08% and Stochastic coefficient D was 82.78%, while ATR was 2.12. Given the Stochastic reading of 94.23% for the 14-day period, the RSI (14) reading has been calculated as 65.04%. As of today, the MACD Oscillator reading stands at 1.81, while the 14-day reading stands at 2.37.

Analyst Ratings

Citigroup launched its rating on Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) to a Buy in a note to investors on May 25, 2022. Amylyx Pharmaceuticals Inc. (AMLX) has been rated Buy by analysts. According to 0 brokerage firms, AMLX is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Amylyx Pharmaceuticals Inc. stock as buy, with 4 recommending it as overweight.

With a median target price of $50.00, the current consensus forecast for the stock is $44.00 – $51.00. Based on these forecasts, analysts predict Amylyx Pharmaceuticals Inc. (AMLX) will achieve an average price target of $48.75.


Please enter your comment!
Please enter your name here